Literature DB >> 25411167

Validation of a commercial dry-form broth microdilution device (Sensititre) for testing tedizolid, a new oxazolidinone.

Ronald N Jones1, Nicole M Holliday2, Paul R Rhomberg3.   

Abstract

Tedizolid, a novel oxazolidinone antibacterial with potent activity against a wide range of Gram-positive pathogens, was recently approved by regulatory authorities for the treatment of acute bacterial skin and skin structure infections. A commercial broth microdilution device (Sensititre; Thermo Fisher Scientific) was validated using 285 selected Gram-positive isolates, and the device was documented to have 100.0% essential and categorical agreement with reference MIC results and excellent MIC endpoint reproducibility.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25411167      PMCID： PMC4298517          DOI： 10.1128/JCM.02769-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  15 in total

1.  Validation of commercial dry-form broth microdilution panels for susceptibility testing of AZD2563, a new long-acting oxazolidinone.

Authors:  R N Jones; T R Anderegg; D J Biedenbach
Journal:  Clin Microbiol Infect       Date:  2003-06       Impact factor: 8.067

2.  TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens.

Authors:  Ronald N Jones; Gary J Moet; Helio S Sader; Rodrigo E Mendes; Mariana Castanheira
Journal:  J Antimicrob Chemother       Date:  2009-02-13       Impact factor: 5.790

3.  Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2009-01-22       Impact factor: 5.790

4.  Linezolid resistance in a clinical isolate of Staphylococcus aureus.

Authors:  S Tsiodras; H S Gold; G Sakoulas; G M Eliopoulos; C Wennersten; L Venkataraman; R C Moellering; M J Ferraro
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

Review 5.  Oxazolidinone antibiotics.

Authors:  D J Diekema; R N Jones
Journal:  Lancet       Date:  2001-12-08       Impact factor: 79.321

6.  Identification of a plasmid-borne chloramphenicol-florfenicol resistance gene in Staphylococcus sciuri.

Authors:  S Schwarz; C Werckenthin; C Kehrenberg
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

7.  Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

8.  In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.

Authors:  Philippe Prokocimer; Paul Bien; Carisa Deanda; Chris M Pillar; Ken Bartizal
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

9.  Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12).

Authors:  Rodrigo E Mendes; Patricia A Hogan; Jennifer M Streit; Ronald N Jones; Robert K Flamm
Journal:  J Antimicrob Chemother       Date:  2014-01-26       Impact factor: 5.790

10.  First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States.

Authors:  Rodrigo E Mendes; Lalitagauri M Deshpande; Mariana Castanheira; Joseph DiPersio; Michael A Saubolle; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191
View more
  3 in total

1.  Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014.

Authors:  Michael A Pfaller; Robert K Flamm; Ronald N Jones; David J Farrell; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 2.  New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.

Authors:  Matthew P Crotty; Tamara Krekel; C A Burnham; David J Ritchie
Journal:  J Clin Microbiol       Date:  2016-03-09       Impact factor: 5.948

3.  Validation of Sensititre Dry-Form Broth Microdilution Panels for Susceptibility Testing of Ceftazidime-Avibactam, a Broad-Spectrum-β-Lactamase Inhibitor Combination.

Authors:  Ronald N Jones; Nicole M Holliday; Kevin M Krause
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.